Of note, the approval of palbociclib, ribociclib, and abemaciclib for HR-positive BC; T-DM1, neratinib, and tucatinib for ERBB2-positive BC; and olaparib for germline BRCA variant BC and atezolizumab (BC indication now withdrawn) took place within the study period.25,30,31,32,33 Our data also demonstrates the rapid adoption of palbociclib and letrozole as first-line therapy for HR-positive and ERBB2-negative MBC since the approval of palbociclib in 2015. Here, ERBB2 is linked to breast cancer.